After the ongoing concerns regarding the cocktail vaccines, a single shot of Regeneron Pharmaceuticals antibody cocktail has reduced the risk of Covid 19 by 81.9 percent for two-eight months. This comes as the results of the phase 3 trials presented by the company.
No Deaths or Hospitalizations Observed For REGEN-COV Group
As per the reports released by the company, during the eight months there were zero hospitalizations for Covid 19 and the deaths in the REGEN-COV group. However, six such incidents were noted in the placebo group.
Myron S. Cohen who leads the monoclonal antibody efforts for the US National Institutes of Health-sponsored Covid Prevention Network said that the results demonstrated that REGEN-COV has the potential to provide long lasting immunity against the Covid 19 infection.
ALSO READ: Covaxin Added to UK’s Vaccine Approval List for International Travellers
Casirivimab and Imdevimab injection is a cocktail of two monoclonal antibodies and was designed specifically to block infectivity of SARS-CoV-2, the virus that causes Covid-19. The monoclonal antibodies are produced by the recombinant DNA technology.
Finding Mainly Important For People Who Don’t Respond To Covid 19 Vaccines
The company further said that the findings are particularly important for those people who don’t respond to the Covid 19 vaccines along with the ones who are immunocompromised. The findings had previously shown an 81.4 percent risk reductin during the first month after administration.
Apart from providing long-term protection against Covid 19, the trial also showed that the drug cocktail prevented high risk from household exposure.
As of now, REGEN-COV has not been approved by the FDA but is authorized in the US for treatment and post exposure prophylaxis. To increase its reach across the world, the company has collaborated with Roche including in India.
Currently, emergency or temporary pandemic use authorizations are in place with more than 40 countries including India, the US, Switzerland and Canada. The antibody cocktail is fully approved in Japan and approved with conditions in UK.